Sarmad Sadeghi is an Oncology physician affiliated with University of Southern California. OpenAlex indexes 95 publications with 542 citations (h-index 13); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Sponsor: Vasgene Therapeutics, Inc
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Sponsor: National Cancer Institute (NCI)
- A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Sponsor: Vasgene Therapeutics, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PfizerProgram year20252 paymentsResearch$359,754openpaymentsdata.cms.gov ↗
- EisaiProgram year20251 paymentResearch$112,000openpaymentsdata.cms.gov ↗
- PfizerProgram year202410 paymentsResearch$1,741,376openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
University of Southern California
FY2026$679,846R01CA293348 - Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
University of Southern California
FY2025$712,735R01CA293348
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Siamak Daneshmand, MD
University of Southern California
David Freyer, DO
University of Southern California
Andrew Moshfeghi, MD
University of Southern California
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”